Senvion S.A.

  • ISIN: LU1377527517
  • Land: Großherzogtum Luxemburg

Nachricht vom 24.04.2019 | 21:25

Senvion S.A.: Changes in the Supervisory Board composition

Senvion S.A. (IRSH)

24-Apr-2019 / 21:25 CET/CEST
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Senvion S.A.: Changes in the Supervisory Board composition

Luxembourg, 24 April 2019 - Members of Supervisory Board of Senvion S.A. ('Senvion') today decided to resign from their office and to hand over their responsibilities and duties effective immediately to three restructuring experts to optimally support the Company and its subsidiaries during the ongoing transformation and restructuring process.

The Management Board thanks the resigning members of the Supervisory Board, i.e. Steven Holliday (chairman), Frank Mattern, Ben Langworthy, Matthias Schubert, Alberto Terol and Carl Friedrich Arp Ole Freiherr von Beust for their commitment and support of the Company.

The new members of the Supervisory Board, Eugene Davis, Steven D. Scheiwe and Timothy Bernlohr, have assumed office with immediate effect by way of co-optation and with a provisional term until the next general meeting of the shareholders of the Company. Eugene Davis has been appointed as new chairman of the Supervisory Board. All three members have extensive experience in supporting companies during restructurings and turn-arounds.

The Management Board

Senvion Investor Relations Contact (Notifying Person):
Anja Siehler
Senior Manager - Capital Markets
Telephone: +352 26 00 - 5285

Anja Siehler
Tel: +352 26 00 5285
Mobil: +4915221817093

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

MS Industrie AG

Original-Research: MS Industrie AG (von Montega AG): Kaufen

29. November 2021